CD40 and myeloid sarcoma: CD192 expression in both MS groups was decreased (19% lower in pwMS with altered MEP latency findings and 13% lower in pwMS with normal MEP latency findings) while their CD40 expression was increased (65% higher in pwMS with altered MEP latency findings and 54% higher in pwMS with normal MEP latency findings) in comparison to healthy control.